Dr. Reddy's Announces Delay in Semaglutide Supply Due to Manufacturing Issue

Dr. Reddy's Laboratories has reported a delay in the commercial availability of its semaglutide injection, attributing the setback to a manufacturing issue with an active pharmaceutical ingredient. The company clarified that this problem affects only new validation batches and poses no safety risk to products already distributed, with supply expected to resume in late October or early November.